Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imgatuzumab
- Development stage
- Phase 2
- Lead developer
- PegaOne
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Imgatuzumab is a humanized monoclonal antibody designed for the treatment of cancer. It targets the epidermal growth factor receptor (EGFR) and acts as an immunomodulator. The drug exerts its antitumor effects through multiple mechanisms, including antagonism of EGFR signaling, inhibition of cell proliferation, induction of apoptosis, and strong antibody-dependent cellular cytotoxicity (ADCC). Imgatuzumab is glycoengineered to enhance ADCC activity. It was developed by Genentech/Roche and later by PegaOne (a subsidiary of Centessa). Clinical development reached up to phase II in several solid tumors but has since been discontinued for all indications[1][2][3][4][6][7][8].
- Other names
- imgatuzumab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on imgatuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imgatuzumab.